Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in pulmonary hypertension
ACTRN12620001349932Phase 4Not yet recruiting
- Sponsor
- Royal Prince Alfred Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mirabegron in pulmonary hypertension (PH) (2 arms), sponsored by Royal Prince Alfred Hospital. Primary endpoint: Change in pulmonary vascular resistance. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on ACTRN12620001349932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001349932.